Does oxypentifylline reduce the intensity of acute graft-versus-host disease following allogeneic bone marrow transplantation?
From 1988 to 1993, a retrospective analysis of the severity of acute graft-versus-host disease (GVHD) was carried out in two groups of patients undergoing allogeneic bone marrow transplantation for various haematological disorders. One group of 23 patients received oxypentifylline in a dose of 400 mg, 6 hourly, orally, day -10 to day +35 in addition to other standard management received by the control group of 20 patients. Acute GVHD was scored in each patient according to the Seattle criteria. Patients receiving oxypentifylline showed a lower GVHD score in each organ-specific area and this reached significance with the total GVHD score. A significantly smaller proportion of patients in the treatment group developed acute GVHD of grade 2 or more. It is concluded that oxypentifylline used in the present dosage reduces the intensity of acute GVHD following allogeneic bone marrow transplantation and is also well tolerated by the patient.
Ghosh
K
K
Hutchinson
R M
RM
D000208:Acute Disease; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013805:Theobromine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014184:Transplantation, Homologous
C007942:pentifylline; D013805:Theobromine